{"id":"clobazam-onfi","safety":{"commonSideEffects":[{"rate":"~30%","effect":"Somnolence"},{"rate":"~15%","effect":"Ataxia"},{"rate":"~10%","effect":"Fatigue"},{"rate":"~5%","effect":"Insomnia"},{"rate":"~5%","effect":"Irritability"},{"rate":"~5%","effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL70418","moleculeType":"Small molecule","molecularWeight":"300.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clobazam binds to GABA-A receptors and increases the frequency of chloride channel opening, thereby enhancing the inhibitory effects of GABA. This results in reduced neuronal excitability and seizure threshold elevation. Unlike many other benzodiazepines, clobazam has a unique 1,5-benzodiazepine structure that may contribute to its selective anticonvulsant properties with potentially lower sedation.","oneSentence":"Clobazam is a benzodiazepine that enhances inhibitory neurotransmission by potentiating GABA-A receptor activity in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:18.962Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome"},{"name":"Adjunctive treatment of other seizure disorders"}]},"trialDetails":[{"nctId":"NCT03196466","phase":"","title":"Population Pharmacokinetics of Antiepileptic in Pediatrics","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-19","conditions":"Epilepsy","enrollment":753},{"nctId":"NCT03678129","phase":"NA","title":"GABA Pathways in Autism Spectrum Disorder (ASD)","status":"COMPLETED","sponsor":"King's College London","startDate":"2018-12-07","conditions":"Autism Spectrum Disorder","enrollment":109},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT05697614","phase":"PHASE4","title":"The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children","status":"UNKNOWN","sponsor":"Dr Cipto Mangunkusumo General Hospital","startDate":"2023-03-01","conditions":"Drug Resistant Epilepsy","enrollment":100},{"nctId":"NCT02565108","phase":"PHASE2","title":"A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-01-20","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT02564952","phase":"PHASE2","title":"An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-03-11","conditions":"Epilepsy","enrollment":18},{"nctId":"NCT03636958","phase":"NA","title":"Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy","status":"WITHDRAWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2021-02-15","conditions":"Refractory Epilepsy","enrollment":""},{"nctId":"NCT03371836","phase":"PHASE4","title":"Use of Clobazam for Epilepsy and Anxiety","status":"COMPLETED","sponsor":"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.","startDate":"2017-10-01","conditions":"Epilepsy, Anxiety","enrollment":20},{"nctId":"NCT02911025","phase":"","title":"Effects of Clobazam on Sleep and Daytime Function in Patients With Epilepsy","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2015-01","conditions":"Epilepsy","enrollment":13},{"nctId":"NCT01713946","phase":"PHASE3","title":"A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04-29","conditions":"Tuberous Sclerosis Complex-associated Refractory Seizures","enrollment":366},{"nctId":"NCT02134366","phase":"PHASE3","title":"Clobazam Use in Epilepsia Partialis Continua - Pilot Study","status":"TERMINATED","sponsor":"The Cooper Health System","startDate":"2014-07","conditions":"Epilepsia Partialis Continua, Kojewnikov's Epilepsy, Epilepsy","enrollment":7},{"nctId":"NCT01160770","phase":"PHASE3","title":"Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome","status":"COMPLETED","sponsor":"Lundbeck LLC","startDate":"2005-12","conditions":"Lennox-Gastaut Syndrome","enrollment":267},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT02727101","phase":"PHASE4","title":"Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.","status":"TERMINATED","sponsor":"Mid-Atlantic Epilepsy and Sleep Center, LLC","startDate":"2015-11","conditions":"Epilepsy","enrollment":8},{"nctId":"NCT02205931","phase":"PHASE4","title":"Ketogenic Diet in Infants With Epilepsy (KIWE)","status":"UNKNOWN","sponsor":"University College, London","startDate":"2015-01","conditions":"Epilepsy","enrollment":160},{"nctId":"NCT02187809","phase":"PHASE3","title":"Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Dravet Syndrome","enrollment":3},{"nctId":"NCT02726919","phase":"PHASE4","title":"Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy","status":"UNKNOWN","sponsor":"Pavel Klein","startDate":"2015-02","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT01932502","phase":"PHASE4","title":"Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy","status":"UNKNOWN","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2013-02","conditions":"Refractory Epilepsy","enrollment":21},{"nctId":"NCT02191358","phase":"","title":"YouScript IMPACT Registry","status":"COMPLETED","sponsor":"Genelex Corporation","startDate":"2014-10","conditions":"Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation","enrollment":800},{"nctId":"NCT01179828","phase":"PHASE3","title":"Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2010-07","conditions":"Low Back Pain","enrollment":150},{"nctId":"NCT02174094","phase":"PHASE3","title":"Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome","status":"WITHDRAWN","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Dravet Syndrome","enrollment":""},{"nctId":"NCT02127918","phase":"","title":"Electrical Status Epilepticus in Sleep: Response of Neuropsychological Deficits and Epileptiform Activity to Clobazam Treatment","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2012-07","conditions":"Electrical Status Epilepticus in Sleep","enrollment":17},{"nctId":"NCT00518713","phase":"PHASE3","title":"Clobazam in Patients With Lennox-Gastaut Syndrome","status":"COMPLETED","sponsor":"Lundbeck LLC","startDate":"2007-08","conditions":"Epilepsy, Epilepsy, Generalized, Seizures","enrollment":238},{"nctId":"NCT00162981","phase":"PHASE2","title":"Clobazam in Subjects With Lennox-Gastaut Syndrome","status":"COMPLETED","sponsor":"Lundbeck LLC","startDate":"2005-10","conditions":"Epilepsy, Epilepsy, Generalized, Seizures","enrollment":68},{"nctId":"NCT01291316","phase":"PHASE1, PHASE2","title":"GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2010-04","conditions":"Neuropathic Pain","enrollment":25},{"nctId":"NCT01011036","phase":"PHASE3","title":"Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2009-12","conditions":"Pain","enrollment":17},{"nctId":"NCT00552526","phase":"PHASE4","title":"Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2007-11","conditions":"Epilepsy, Mental Retardation","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"clobazam (Onfi)","genericName":"clobazam (Onfi)","companyName":"St. Joseph's Hospital and Medical Center, Phoenix","companyId":"st-joseph-s-hospital-and-medical-center-phoenix","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clobazam is a benzodiazepine that enhances inhibitory neurotransmission by potentiating GABA-A receptor activity in the central nervous system. Used for Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, Adjunctive treatment of other seizure disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}